]
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sonoma Pharmaceuticals’s 8K filing here.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
Featured Articles
- Five stocks we like better than Sonoma Pharmaceuticals
- Stock Dividend Cuts Happen Are You Ready?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Insider Buying Explained: What Investors Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
